Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant
The phase III clinical trial, EMERALD, is currently underway to assess the efficacy of elacestrant versus standard of care endocrine therapy in the overall population, as well as in patients who have been comprehensively genotyped using the Guardant360 test and harbor ESR1 mutations. Radius recently signed a global exclusive development and commercialization licensing agreement with
“Given breast cancer’s inherent tumor heterogeneity and the high prevalence of bone metastasis in advanced disease, our Guardant360 liquid biopsy can help overcome the challenges of tissue and bone biopsies to reveal significantly more actionable mutations, including ESR1 mutations, which may play a role in resistance and which are being studied in Radius’ EMERALD trial,” said AmirAli Talasaz, Ph.D.,
The Guardant360 blood test is increasingly being used to guide treatment in metastatic breast cancer, as the number of treatment-relevant genomic alterations continues to grow. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from patient blood samples. The Guardant360 test is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding any regulatory approval to be pursued by
Source: Guardant Health, Inc.